Mayne Pharma Group (AU:MYX) has released an update.
Mayne Pharma Group Limited reports a substantial financial upswing in FY24, with reported revenue skyrocketing by 112% to $388.4 million and underlying EBITDA turning around to $22.9 million from a prior loss. The growth was buoyed by significant gains across all business segments, particularly Women’s Health and Dermatology, and was complemented by disciplined operational expenditure and a solid cash reserve position.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.
